Trial Profile

Randomized Double-Blind Placebo Controlled Phase II Study of a Galectin-3 Inhibitor (GB1211) and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Selvigaltin (Primary)
Indications Carcinoma; Head and neck cancer; Malignant melanoma; Squamous cell cancer
Focus Therapeutic Use

07 Oct 2024 According to a Galecto Biotech media release, this trial was initiated and enrolled its first patient in the second quarter of 2024.
01 May 2024 According to a Galecto Biotech media release, the early data of this study could be available as early as 2025.
01 May 2024 According to a Galecto Biotech media release, the first patient of this study has been enrolled and dosed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com